In addition, Man-clod treatment effectively depleted CD206+ TAMs—those often associated with pro-tumoral, anti-inflammatory phenotypes—underscoring the specificity and therapeutic relevance of mannose-receptor targeting in the tumor microenvironment. The gene discussed is MRC1; the disease is neoplasm.